关注
Susana Roselló
Susana Roselló
Medical Doctor in Hospital Clinico Universitario of Valencia, Spain
在 incliva.es 的电子邮件经过验证
标题
引用次数
引用次数
年份
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
A Cervantes, R Adam, S Roselló, D Arnold, N Normanno, J Taïeb, ...
Annals of Oncology 34 (1), 10-32, 2023
6282023
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
N Tarazona, F Gimeno-Valiente, V Gambardella, S Zuñiga, ...
Annals of Oncology 30 (11), 1804-1812, 2019
2342019
Current questions for the treatment of advanced gastric cancer
A Cervantes, D Roda, N Tarazona, S Roselló, JA Pérez-Fidalgo
Cancer treatment reviews 39 (1), 60-67, 2013
2282013
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ...
Breast cancer research and treatment 114, 479-484, 2009
2222009
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
V Gambardella, J Castillo, N Tarazona, F Gimeno-Valiente, ...
Cancer treatment reviews 86, 102015, 2020
2212020
Personalized medicine: recent progress in cancer therapy
V Gambardella, N Tarazona, JM Cejalvo, P Lombardi, M Huerta, ...
Cancers 12 (4), 1009, 2020
1942020
A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors
C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ...
Cancer discovery 7 (1), 102-113, 2017
1712017
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors
A Cervantes, E Elez, D Roda, J Ecsedy, T Macarulla, K Venkatakrishnan, ...
Clinical cancer research 18 (17), 4764-4774, 2012
1692012
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer
F Sclafani, G Brown, D Cunningham, A Wotherspoon, LST Mendes, ...
British journal of cancer 117 (10), 1478-1485, 2017
1652017
Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences
TV Henriksen, N Tarazona, A Frydendahl, T Reinert, F Gimeno-Valiente, ...
Clinical Cancer Research 28 (3), 507-517, 2022
1472022
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
J Tabernero, A Cervantes, F Rivera, E Martinelli, F Rojo, ...
Journal of clinical oncology 28 (7), 1181-1189, 2010
1402010
Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer
M Frasson, E Garcia‐Granero, D Roda, B Flor‐Lorente, S Roselló, ...
Cancer 117 (14), 3118-3125, 2011
1342011
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
S Roselló, I Blasco, LG Fabregat, A Cervantes, K Jordan, ...
Annals of Oncology 28, iv100-iv118, 2017
1322017
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
1312011
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
J Tabernero, F Ciardiello, F Rivera, E Rodriguez-Braun, FJ Ramos, ...
Annals of oncology 21 (7), 1537-1545, 2010
1102010
The treatment of advanced gastric cancer: current strategies and future perspectives
A Cervantes, S Roselló, D Roda, E Rodriguez-Braun
Annals of oncology 19, v103-v107, 2008
1022008
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
T Macarulla, A Cervantes, E Elez, E Rodríguez-Braun, J Baselga, ...
Molecular cancer therapeutics 9 (10), 2844-2852, 2010
962010
Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer
R Dienstmann, A Patnaik, R Garcia-Carbonero, A Cervantes, M Benavent, ...
Cancer Discovery 5 (6), 598-609, 2015
832015
How we treat metastatic colorectal cancer
V De Falco, S Napolitano, S Roselló, M Huerta, A Cervantes, F Ciardiello, ...
ESMO open 4, e000813, 2019
812019
Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens
JA Pérez-Fidalgo, S Roselló, E García-Garré, E Jordá, P Martín-Martorell, ...
Breast cancer research and treatment 120, 245-251, 2010
812010
系统目前无法执行此操作,请稍后再试。
文章 1–20